Outlook Therapeutics, Inc. (OTLK) Earnings

Management highlights

- FDA Approval Achievement • The FDA recently approved LightNava, the only FDA-approved ophthalmology formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) in the U.S. • This is a transformational milestone that provides U.S. physicians with an FDA-compliant bevacizumab formulation developed specifically for ocular use, replacing reliance on off-label repackaged/compounded product. • The approved label includes statistically significant and clinically meaningful visual acuity improvement data from the NORS II trial, where 41.7% of LightNava-treated patients gained at least 15 letters of visual acuity at month 11, compared to 23.1% of patients treated with ranibizumab. - U.S. Commercial Launch Preparation • The total U.S. anti-VEGF retina market is ~$8.5 billion annually, with ~2.2 million annual off-label bevacizumab injections for wet AMD alone. LightNava targets this established market with a differentiated value proposition, and has a base case peak U.S. sales target of $500 million by 2030 (assuming repackaged bevacizumab remains available in the market). • Pricing is set to be below $500 per vial, designed to be competitive with biosimilars while supporting patient affordability, broad payer access, and practice adoption. • The company is building a targeted commercial organization: ~30 customer-facing field personnel focused on retina specialists, ~20 field reimbursement personnel to support practice access and operations, and an expanded medical affairs team to lead scientific exchange and real-world evidence generation. • Key priorities include payer engagement, securing a permanent HCPCS J-code (expected April 2027, with a code submission planned by end-Q3 2026), and building sufficient commercial supply for launch. • The market is highly concentrated: a small group of high-volume retina practices accounts for most bevacizumab injections. The company has identified ~800 potential early adopter physicians (roughly one-third of total target retina physicians) that represent almost half of the 2030 peak sales opportunity. - European Operations • LightNava is already commercially available in Germany and the United Kingdom, with launch preparations ongoing for the Netherlands and Austria. Partner MediConsult expects to launch in Switzerland in 2027. • The company has right-sized its European cost structure to align with current revenue, and has begun seeing accelerating unit sales growth. Management is taking a strategic, slow approach to further European expansion focused on executing well in existing markets before scaling further. - Financial Update • As of June 30, 2026, the company held $11.2 million in cash and cash equivalents. A $55 million public offering completed after quarter-end is expected to deliver ~$51.1 million in net proceeds, which will be used to fund the U.S. commercial launch and general working capital needs.

Guidance

- Peak Sales: Management maintains a base case peak U.S. sales target of $500 million for LightNava by 2030, with potential upside of up to ~$300 million if regulatory action disrupts the compounded/repackaged bevacizumab market. Europe is expected to reach less than a quarter of the U.S. peak sales opportunity by 2030, with the U.S. expected to account for 90% or more of total net revenue. - First 12 Months Post-U.S. Launch: Total net revenue is projected to be between $50 million and $75 million, with Europe contributing 10% to 15% of that total. Revenue is expected to ramp progressively, with ~10% of first-year revenue generated in the first three months post-launch, and ~50% generated in the fourth quarter post-launch, with acceleration driven by the expected permanent J-code approval in April 2027. - Operating Expenses: Quarterly SG&A expenses are expected to approximately double from current levels by the end of 2026, followed by an additional 10% increase during 2027. R&D expenses are expected to remain relatively steady over the next 12 months as the company advances its pre-filled syringe development program.

Segment performance

Outlook Therapeutics currently operates two geographic commercial segments: U.S. and Europe. The U.S. segment has not yet generated revenue, as the commercial launch of LightNava is still in preparation. The European segment reported improving revenue performance, with Q3 fiscal 2026 unit sales increasing 46% compared to Q2 fiscal 2026. Europe is expected to contribute 10% to 15% of total net revenue in the first 12 months following the U.S. launch of LightNava. On a consolidated basis, the company reported an adjusted net loss attributable to common stockholders of $10.9 million ($0.09 per basic/diluted share) for Q3 fiscal 2026, compared to an adjusted net loss of $15.8 million ($0.44 per basic/diluted share) in the year-ago quarter.

Risks & headwinds

- Commercial adoption depends on multiple external factors: successful payer reimbursement negotiations, securing the expected permanent J-code on schedule, practice willingness to switch from existing off-label bevacizumab, and patient affordability for the product. - Increasing competitive and pricing pressure: Recent entry of bevacizumab and ranibizumab biosimilars has created downward pricing pressure across the anti-VEGF market, and additional new therapies (longer-acting agents, gene therapy, IL-6 inhibitors) are expected to enter the market in coming years. - European market challenges: Many European markets have existing regulatory and standard-of-care barriers to adoption (e.g., mandatory use of compounded product in German retina practices), broad industry-wide pricing and reimbursement pressure, and slow reimbursement approval timelines that can delay revenue growth. - Dependence on third-party partnerships for international expansion, and additional clinical bridging data may be required to gain approval in new regions outside the U.S. and EU. - Potential disruption of the Good Days Foundation patient funding support can increase patient out-of-pocket cost burdens that may limit adoption. - Uncertainty around potential future FDA regulatory action on large-scale compounded bevacizumab operations, which could create both upside and unexpected market shifts.

Analyst Q&A

• Q: What upside to the 2030 $500 million U.S. sales target would there be if the FDA restricts large-scale compounded bevacizumab operations? How many early adopters have been identified, and what market share do they represent? What are LightNava's advantages over repackaged bevacizumab for payers and prescribers? /

  A: Management states there is up to ~$300 million in conservative estimated upside to the 2030 target if compounded bevacizumab availability is disrupted, with some of the displaced volume potentially going to other biosimilars. They have identified just under 800 early adopter physicians (about one-third of target retina specialists) that represent almost half of the base $500 million 2030 opportunity. Over two-thirds of payers require providers to trial cheaper bevacizumab before accessing newer branded agents, so LightNava fills an unmet need for an FDA-approved option in this required step therapy pathway.

• Q: How did changing competitive dynamics from new biosimilars impact your 2030 sales forecast, and why is it higher than consensus expectations? /

  A: The forecast already assumes all scheduled biosimilars enter on time, ongoing downward pricing pressure, upcoming approvals of new competing therapies (TTIs, gene therapy, IL-6 inhibitors), continued availability of repackaged bevacizumab, and ongoing pressure from reduced Good Days Foundation patient funding. Management confirms the forecast is intentionally conservative, with built-in upside from potential compounded market disruption, pre-filled syringe launch, and faster adoption after J-code approval. Management expects some practices will continue to use repackaged bevacizumab long-term, and the strategy focuses on incremental growth from early adopters first.

• Q: How will reduced Good Days Foundation funding impact patient out-of-pocket costs and adoption of LightNava, compared to existing options? /

  A: Good Days Foundation funding is now limited and prioritized for more expensive long-acting branded therapies, which has increased cost pressure for patients using lower-priced options. While 20% Medicare cost sharing would lead to ~$100 out-of-pocket for patients without supplemental coverage, this is not universal: most patients have supplemental Medigap, commercial insurance, or Medicare Advantage that reduces out-of-pocket costs. LightNava's list price will be lower than most existing biosimilars and branded options, and the company will leverage existing patient assistance frameworks to minimize cost burdens for patients. LightNava also changes practice economics by providing a J-code for reimbursement that compounded products do not have, which benefits practices.

• Q: Will FDA approval accelerate European and international expansion, including entry into Asian markets? /

  A: Management confirms it is now assessing regional expansion into new markets including LATAM, Asia, and MENA, with inbound inquiries from potential partners. Additional bridging studies will likely be required for some regions, so expansion will be pursued strategically. Broader European expansion will be accelerated after the pre-filled syringe product is available, as country-by-country reimbursement approval takes significant time, and the company is currently focused on improving execution in existing European markets before expanding further.